Eglin C CTRL-Resistance Determinants
Structural determinants (Gln192, Lys218) explaining why eglin C, a classical broad-spectrum chymotrypsin / elastase inhibitor, poorly inhibits human chymotrypsin-like protease — Németh 2024.
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Structural determinants (Gln192, Lys218) explaining why eglin C, a classical broad-spectrum chymotrypsin / elastase inhibitor, poorly inhibits human chymotrypsin-like protease — Németh 2024.
- Evidence level
- Mechanistic discussion
- Drug vs leech
- Purified natural compound
Clinical translation limit
Eglin C-CTRL structural finding refines protease-target selectivity but does NOT directly translate to clinical therapeutic effect. No FDA-approved eglin C derivative.
Molecular Profile
- Category
- Proteinase Inhibitor
- Evidence tier
- Preclinical
- Source species
- Hirudo medicinalis (eglin C)
- Discovered
- 2024 · Németh BZ et al.
Biological Targets
- → chymotrypsin (CTRA, broad); chymotrypsin-like protease (CTRL, weak); pancreatic elastase
Key Citations
- Németh BZ et al. (2024), Proteins · PMID 39301701
External Resources
Related Proteinase Inhibitor Compounds
Hirustasin
Serine proteinase inhibitor targeting tissue kallikrein — anti-inflammatory pathway.
Eglin C
Potent inhibitor of human leukocyte elastase and cathepsin G — anti-inflammatory protein widely used as research tool.
Bdellin B3
Kazal-type proteinase inhibitor targeting trypsin and plasmin — modulates inflammatory cascade.
LDTI (Leech-Derived Tryptase Inhibitor)
Selective inhibitor of human mast cell tryptase — anti-inflammatory pathway.